NICE draft guidance refuses pembrolizumab plus axitinib combination

The National Institute for Health and Care Excellence (NICE) have issued an interim decision not to recommend the pembrolizumab plus axitinib combination as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Appraisal Consultation Document (ACD) released this week, NICE stated that there was uncertainty about the long-term […]

read more

New first-line immunotherapy plus TKI combinations for metastatic kidney cancer

Approval of axitinib plus pembrolizumab and axitinib plus avelumab in the first-line treatment of metastatic renal cell carcinoma (RCC) by both the Food and Drug Administration (FDA) in America and the European Commission represent milestone events for the treatment of metastatic RCC in 2019. Approval of the avelumab plus axitinib combination was based on the […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

European Commission approves avelumab plus axitinib combination for the first-line treatment of advanced kidney cancer

Based on the findings from the pivotal phase III JAVELIN Renal 101 study, the European Commission has approved avelumab in combination with axitinib for the first-line treatment of advanced renal cell carcinoma (RCC). JAVELIN Renal 101 demonstrated that avelumab in combination with axitinib significantly lowered risk of disease progression or death by 31% and nearly […]

read more

ESMO 2019: Kidney cancer tumour shrinkage in patients who did not have surgery

This interview with Dr Monty Pal, Associate Professor from the City of Hope National Medical Center in California, USA discusses tumour shrinkage in patients who did not have a nephrectomy. The interview was conducted at the European Society of Medical Oncology (ESMO) 2019 conference in Barcelona earlier this month. Dr Pal discusses the results from […]

read more

ESMO 2019: First-line avelumab plus axitinib in sarcomatoid kidney cancer – results from JAVELIN Renal 101

Results from the JAVELIN Renal 101 study to evaluate avelumab plus axitinib in untreated sarcomatoid renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid differentiation can occur in all subtypes of renal cell carcinoma (RCC) and is an aggressive form of RCC. JAVELIN […]

read more

ESMO 2019: Avelumab plus axitinib in patients who had not had nephrectomy

Results from a post-hoc analysis of JAVELIN-Renal 101 in patients with advanced renal cell carcinoma (RCC) who had not had a prior nephrectomy were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. The JAVELIN Renal 101 study demonstrated a significant improvement in progression-free survival with avelumab plus axitinib […]

read more

ESMO 2019: Results from the TRAXAR study to assess TRC105 plus axitinib for metastatic kidney cancer

Results from the TRAXAR clinical trial to assess TRC105 plus axitinib in pre-treated patients with advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Endoglin is an endothelial cell surface receptor that has a role in the development and growth of blood vessels (angiogenesis) […]

read more

ESMO 2019: Results from JAVELIN-Renal 101 trial for sarcomatoid kidney cancer

Results from the JAVELIN-Renal 101 clinical trial to assess avelumab plus axitinib in untreated patients with advanced renal cell carcinoma (RCC) with sarcomatoid characteristics were presented at the European Society for Medical Oncology (ESMO) conference in Barcelona over the weekend. Sarcomatoid RCC is an uncommon but highly aggressive form of RCC, which tends to have […]

read more

European Medicines Agency approves avelumab plus axitinib for first-line treatment of advanced kidney cancer

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) today recommended the approval of the combination of avelumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma (RCC). This recommendation is based on findings from the phase III JAVELIN Renal 101 study involving 886 patients, which demonstrated significant improvements in median […]

read more
Showing 1 to 10 of 51 results
  TOP